Qualigen Therapeutics, Inc.

NasdaqCM:QLGN

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 2.63 M

Share Price

USD 3.44

Avg Daily Volume

57,503

Change (1 day)

-3.64%

Change (1 year)

-61.86%

Change (YTD)

-18.29%

Qualigen Therapeutics, Inc. Market Capitalization on June 25, 2025: USD 2.63 M

Qualigen Therapeutics, Inc. Market Capitalization is USD 2.63 M on June 25, 2025, a 2,779.86% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Qualigen Therapeutics, Inc. 52-week low Market Capitalization is USD 3.75 M on June 25, 2025, which is 42.62% above the current Market Capitalization.
Qualigen Therapeutics, Inc. 52-week low Market Capitalization is USD 72.78 K on June 25, 2025, which is -97.23% below the current Market Capitalization.
Qualigen Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 1.85 M.

Daily

From:

To:

Zoom:

Key data

Date	Market Capitalization	Share Price	Share Price	Price to Earnings Ratio (P/E)

NasdaqCM: QLGN

Qualigen Therapeutics, Inc.

CEO	Mr. Kevin A. Richardson II
IPO Date	June 23, 2015
Location	United States
Headquarters	2042 Corte Del Nogal
Employees	4
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 💊 Pharmaceuticals

Description

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.